FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

This study aimed to test whether [(18)F]fluoro-D-glucose (FDG) uptake of tumours measured by positron emission tomography (PET) can be used as surrogate marker to define the optimal biological dose (OBD) of mTOR inhibitors in vivo. Everolimus at 0.05, 0.5, 5 and 15 mg kg(−1) per day was administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Cejka, D, Kuntner, C, Preusser, M, Fritzer-Szekeres, M, Fueger, B J, Strommer, S, Werzowa, J, Fuereder, T, Wanek, T, Zsebedics, M, Mueller, M, Langer, O, Wacheck, V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695687/
https://www.ncbi.nlm.nih.gov/pubmed/19436299
http://dx.doi.org/10.1038/sj.bjc.6605076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695687/
https://www.ncbi.nlm.nih.gov/pubmed/19436299
http://dx.doi.org/10.1038/sj.bjc.6605076

Ejemplares similares